<DOC>
	<DOCNO>NCT02399943</DOCNO>
	<brief_summary>This phase 2 study ( second phase test new drug drug combination ) see useful combination two drug , panitumumab trametinib , patient advance colorectal cancer KRAS , NRAS , BRAF wild type ( gene mutate ) . Panitumumab drug approve Health Canada treatment advance colorectal cancer KRAS wild type . Panitumumab work bind block protein , epidermal growth factor receptor ( EGFR ) work . Trametinib drug approve Health Canada treatment melanoma mutation BRAF gene . Trametinib work bind block mitogen-activated protein kinase kinase ( MEK ) 1 MEK2 work . Previous study show combination panitumumab trametinib may useful KRAS , NRAS , BRAF wild type colorectal cancer .</brief_summary>
	<brief_title>A Trial Trametinib Panitumumab RAS/RAF Wild Type Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>18 year age old KRAS/NRAS/BRAF wild type colorectal cancer , responsive standard therapy , approve curative therapy , refuse standard therapy Prior 5FU , oxaliplatin irinotecan ECOG Performance Status 0 1 Able swallow/retain oral drug Able agree provide tumor tissue/have biopsy Agree use contraception Not pregnant Adequate organ system function Chemotherapy , radiotherapy , immunotherapy , anticancer therapy &lt; 28 day 5 half life Prior EGFR , MEK , RAF inhibitor regorafenib Current use prohibit medication Unresolved side effect GI disease condition affect GI absorption Mucosal internal bleeding Any major surgery &lt; four week HIV , HBV , HCV positive Active infection Leptomeningeal disease Brain metastases Unacceptable QTcF interval Significant uncontrolled arrhythmias Acute coronary syndrome , myocardial infarction , coronary angioplasty , stenting bypass graft &lt; 6 mo . Class II , III , IV heart failure Other clinically significant ECGs Intra cardiac defibrillator Cardiac metastasis Condition may interfere patient safety Hypersensitivity study drug Severe uncontrolled systemic disease Pregnant lactate Retinal vein occlusion Interstitial lung disease pneumonitis Active liver biliary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>